JACC. Cardiovascular interventions
JACC. Cardiovascular interventions
Audio Summaries
Every issue of JACC. Cardiovascular interventions moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Specialties
JACC. Cardiovascular interventions covers research in these specialties.
Recent summaries
The latest articles summarized from JACC. Cardiovascular interventions.
Sex-Related Differences in Patients Undergoing Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation: PRIME-MR Registry Insights.
Nov 20, 2026
This retrospective international registry study of 2,078 patients (46.3% female) undertaking transcatheter edge-to-edge repair (TEER) for primary mitral regurgitation asked whether sex influences baseline profiles and outcomes. Females were older, had fewer comorbidities, and more advanced symptoms, with less optimal procedural results (more residual MR ≥2+ and higher mean gradients), yet after adjustment they had lower 2-year all-cause and cardiovascular mortality and a lower composite of mortality or heart failure hospitalization. The authors conclude that TEER is a good option for patients with primary MR regardless of sex.
Development of a Quantitative Contrast CT-Based TAVR-Risk Score to Reliably Predict Deformation in Bicuspid Aortic Valves.
Nov 9, 2026
This study developed a contrast-enhanced CT-based "BAV TAVR-risk score" to grade bicuspid aortic valve calcification and predict transcatheter heart valve deformation (underexpansion and eccentricity) after balloon-expandable TAVR in 321 retrospectively analyzed patients. The authors asked whether a quantitative calcification score could reliably identify patients at risk of valve deformation: high-risk scores were strongly associated with underexpansion and eccentricity (OR 89.13), and 96% of low-risk patients showed no deformation. These findings suggest the score may help guide pre-procedural decision-making in patients with bicuspid valves, though validation in external cohorts is needed.
Transcatheter vs Surgical Aortic Valve Replacement for Isolated Native Aortic Regurgitation: National Propensity-Matched Analysis.
Nov 9, 2026
This national Medicare propensity-matched study asked whether off-label TAVR offers outcomes comparable to SAVR for patients ≥65 with isolated native aortic regurgitation. Among 1,742 matched pairs, TAVR was associated with shorter hospitalization and lower in-hospital mortality, but higher 30-day pacemaker implantation and more repeat aortic valve replacement at 5 years. All-cause mortality and heart failure readmission were similar between strategies through a median follow-up of 2.6 years.
Prevalence and Consequences of Guideline-Directed Indications for Aortic Valve Replacement in the EARLY TAVR Trial.
Nov 9, 2026
This post hoc analysis of the EARLY TAVR trial asked how often patients with asymptomatic severe aortic stenosis meet ACC/AHA Class II guideline indications for valve replacement at baseline, and whether early TAVR's benefit differs in these patients. About 29% had a Class II indication, and they had higher event rates than those without (24.5% vs 14.5% for death, stroke, or heart failure hospitalization), but the benefit of early TAVR over clinical surveillance was consistent across both groups (interaction P = 0.96). These findings support early TAVR in asymptomatic severe AS regardless of whether Class II guideline indications are present.
Prosthesis-Patient Mismatch and Patient-Centered Outcomes After TAVR.
Nov 9, 2026
This post hoc analysis of the SCOPE I randomized trial asked whether prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement affects patient-reported health status through 3 years. Among 662 patients, severe PPM was associated with lower odds of being alive with good health status at 3 years (OR 0.51), though this association was attenuated after adjusting for 30-day residual mitral regurgitation (OR 0.59, not significant). Because the analysis was post hoc, the authors describe the findings as hypothesis-generating, suggesting residual mitral regurgitation may partly explain the link between severe PPM and poorer patient-reported outcomes.
Prognostic Impact of Paravalvular Regurgitation in Patients With Severe Low-Flow, Low-Gradient Aortic Stenosis Undergoing TAVR.
Nov 9, 2026
This multicenter Italian registry study of 1,358 patients with low-flow, low-gradient aortic stenosis undergoing TAVR asked whether paravalvular regurgitation (PVR) severity affects outcomes with current-generation valves. Moderate-or-worse PVR (≥2+) at discharge was independently associated with a substantially higher risk of the composite of all-cause death or heart failure hospitalization over 2 years (adjusted HR 3.77), with the association consistent across classical and paradoxical LFLG phenotypes.
Cardiac Damage and Clinical Outcomes in Symptomatic Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.
Nov 9, 2026
This post hoc analysis of the LANDMARK trial asked whether an updated, staged cardiac damage classification (incorporating echocardiographic pulmonary hypertension probability) can predict outcomes in 596 patients with severe aortic stenosis undergoing TAVR. One-year mortality rose stepwise across stages, from 0% in stage 0 to 20.4% in stage 4 (right ventricular damage), and patients with cumulative damage had the highest mortality at 23.6%. Stage 4 was independently associated with 1-year mortality, supporting comprehensive echocardiographic assessment for risk stratification in severe AS.
3-Year Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Artery Disease: The SIRONA Trial.
Nov 3, 2026
The SIRONA randomized trial asked whether sirolimus-coated balloons (SCB) offer better outcomes than paclitaxel-coated balloons (PCB) for symptomatic femoropopliteal artery disease over 3 years. Among 482 patients, walking capacity, quality of life, mortality, amputation, and amputation-free survival did not differ between groups, though freedom from clinically driven target lesion revascularization was higher with SCB (88.2% vs. 80.2%, HR 0.60). Because this 3-year cdTLR finding was exploratory and not adjusted for multiple comparisons, and the treatment effect appeared to vary over time, it requires confirmation.
Rotational Atherectomy Plus Intravascular Lithotripsy Versus Intravascular Lithotripsy Alone for Coronary Calcified Nodules: The NODULE-SHOCK Trial.
Nov 2, 2026
The NODULE-SHOCK trial asked whether adding rotational atherectomy (RA) to intravascular lithotripsy (IVL) improves lesion preparation for coronary calcified nodules, and whether maximum IVL pulses improve results in severe calcification without nodules. In 120 randomized patients, RA plus IVL produced a significantly larger minimum stent area at the nodule site than IVL alone (7.41 vs 6.23 mm²), whereas maximum versus operator-determined IVL pulses made no meaningful difference (5.50 vs 5.56 mm²). The authors conclude that RA adjunctive therapy benefits calcified nodules, but larger multicenter trials with clinical endpoints are needed to confirm these findings.
1-Year Safety and Effectiveness of a Next-Generation Dual-Seal Left Atrial Appendage Occluder.
Nov 2, 2026
The VERITAS study asked whether a next-generation dual-seal left atrial appendage occluder could provide safe and effective stroke prevention through 1 year in patients with atrial fibrillation who seek an alternative to long-term oral anticoagulation. In this single-arm, prospective, global trial, complete LAA closure (0 mm peridevice leak) was seen in 91.1% of patients by TEE or CT (96.3% by TEE alone), with a cumulative device-related thrombus rate of 3.3% and no device embolizations. One-year outcomes included all-cause mortality of 3.9%, major bleeding of 6.6%, and ischemic stroke or systemic embolism of 1.8%, supporting the device's 1-year safety and effectiveness.
